Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Enterprise Value (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Enterprise Value for 7 consecutive years, with -$82.0 million as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Enterprise Value rose 35.85% year-over-year to -$82.0 million, compared with a TTM value of -$82.0 million through Sep 2019, up 35.85%, and an annual FY2018 reading of -$118.1 million, down 15.69% over the prior year.
  • Enterprise Value was -$82.0 million for Q3 2019 at Larimar Therapeutics, up from -$91.7 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$75.8 million in Q2 2018 and bottomed at -$204.0 million in Q3 2015.
  • Average Enterprise Value over 5 years is -$119.5 million, with a median of -$106.9 million recorded in 2015.
  • Peak annual rise in Enterprise Value hit 37.74% in 2015, while the deepest fall reached 177.87% in 2015.
  • Year by year, Enterprise Value stood at -$185.1 million in 2015, then soared by 30.2% to -$129.2 million in 2016, then rose by 21.01% to -$102.1 million in 2017, then decreased by 15.69% to -$118.1 million in 2018, then skyrocketed by 30.54% to -$82.0 million in 2019.
  • Business Quant data shows Enterprise Value for LRMR at -$82.0 million in Q3 2019, -$91.7 million in Q2 2019, and -$104.7 million in Q1 2019.